Q4 2023 Holdings
Filed 2024-02-14 | 70 holdings | $4.0B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Moonlake Immunotherapeutics(MLTX) | CLASS A ORD | 61559X104 | $1.3B | 21,751,284 | 32.9% |
| Revolution Medicines Inc(RVMD) | COM | 76155X100 | $171.5M | 5,981,212 | 4.3% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $157.7M | 1,981,100 | 3.9% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $131.7M | 5,744,848 | 3.3% |
| Kymera Therapeutics Inc(KYMR) | COM | 501575104 | $131.4M | 5,161,801 | 3.3% |
| Mirum Pharmaceuticals Inc(MIRM) | COM | 604749101 | $129.0M | 4,370,024 | 3.2% |
| Olema Pharmaceuticals Inc(OLMA) | COM | 68062P106 | $128.2M | 9,135,893 | 3.2% |
| Ionis Pharmaceuticals Inc(IONS) | COM | 462222100 | $122.9M | 2,428,613 | 3.1% |
| Kura Oncology Inc(KURA) | COM | 50127T109 | $106.0M | 7,373,228 | 2.7% |
| 4D Molecular Therapeutics in(FDMT) | COM | 35104E100 | $81.2M | 4,007,413 | 2.0% |
| Galapagos NV(GLPG) | SPON ADR | 36315X101 | $77.8M | 1,915,109 | 1.9% |
| Merus N V | COM | N5749R100 | $75.7M | 2,752,420 | 1.9% |
| Repare Therapeutics Inc(RPTX) | COM | 760273102 | $75.4M | 10,333,600 | 1.9% |
| AC Immune SA(ACIU) | SHS | H00263105 | $72.9M | 14,571,236 | 1.8% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADS | 152309100 | $69.8M | 8,774,570 | 1.7% |
| Xoma Corp del(XOMA) | COM NEW | 98419J206 | $67.2M | 3,633,743 | 1.7% |
| Ideaya Biosciences Inc(IDYA) | COM | 45166A102 | $61.5M | 1,729,043 | 1.5% |
| Zymeworks Inc(ZYME) | COM | 98985Y108 | $61.0M | 5,870,000 | 1.5% |
| GH Research PLC(GHRS) | ORDINARY SHARES | G3855L106 | $60.3M | 10,400,158 | 1.5% |
| Essa Pharma Inc(EPIEUR) | COM NEW | 29668H708 | $57.7M | 8,748,629 | 1.4% |
| Janux Therapeutics Inc(JANX) | COM | 47103J105 | $49.1M | 4,579,818 | 1.2% |
| Third Harmonic BIO Inc(THRD) | COM | 88427A107 | $47.9M | 4,365,933 | 1.2% |
| 89Bio Inc(ETNBGBP) | COM | 282559103 | $45.2M | 4,047,354 | 1.1% |
| Relay Therapeutics Inc(RLAY) | COM | 75943R102 | $43.7M | 3,970,045 | 1.1% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $41.0M | 890,072 | 1.0% |
| Syndax Pharmaceuticals Inc(SNDX) | COM | 87164F105 | $40.5M | 1,875,000 | 1.0% |
| Tyra Biosciences Inc(TYRA) | COM | 90240B106 | $37.9M | 2,739,595 | 0.9% |
| Lexicon Pharmaceuticals Inc(LXRX) | COM NEW | 528872302 | $37.4M | 24,435,632 | 0.9% |
| Structure Therapeutics Inc(GPCR) | SPONSORED ADS | 86366E106 | $33.1M | 812,988 | 0.8% |
| Cullinan Oncology Inc(CGEM) | COM | 230031106 | $32.6M | 3,196,701 | 0.8% |
| An2 Therapeutics Inc(ANTX) | COM | 037326105 | $32.0M | 1,563,963 | 0.8% |
| Annexon Inc(ANNX) | COM | 03589W102 | $31.8M | 7,000,000 | 0.8% |
| Roivant Sciences LTD(ROIV) | SHS | G76279101 | $30.8M | 2,742,409 | 0.8% |
| Silence Therapeutics PLC(SLN) | ADS | 82686Q101 | $26.2M | 1,508,416 | 0.7% |
| Allakos Inc(ALLKGUSD) | COM | 01671P100 | $23.3M | 8,552,417 | 0.6% |
| Glycomimetics Inc(GLYCEUR) | COM | 38000Q102 | $22.5M | 9,544,262 | 0.6% |
| Ovid Therapeutics Inc(OVID) | COM | 690469101 | $22.1M | 6,851,051 | 0.6% |
| Engene Holdings Inc(ENGN) | COM | 29286M105 | $20.8M | 2,251,037 | 0.5% |
| Calliditas Therapeutics AB | SPONSERED ADS | 13124Q106 | $19.3M | 750,000 | 0.5% |
| Tscan Therapeutics Inc(TCRX) | COM | 89854M101 | $17.4M | 2,989,474 | 0.4% |
| Newamsterdam Pharma Company(NAMS) | ORDINARY SHARES | N62509109 | $17.0M | 1,521,948 | 0.4% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $14.8M | 687,080 | 0.4% |
| Sutro Biopharma Inc | COM | 869367102 | $14.4M | 3,347,946 | 0.4% |
| Iteos Therapeutics Inc(5E7) | COM | 46565G104 | $13.8M | 1,259,476 | 0.3% |
| Verastem Inc(VSTM) | COM NEW | 92337C203 | $13.7M | 1,685,219 | 0.3% |
| Immunovant Inc(IMVT) | COM | 45258J102 | $12.6M | 300,000 | 0.3% |
| Vistagen Therapeutics Inc(VTGN) | COM | 92840H400 | $10.3M | 2,000,000 | 0.3% |
| Cytomx Therapeutics Inc(CTMX) | COM | 23284F105 | $10.2M | 6,595,801 | 0.3% |
| Ikena Oncology Inc | COM | 45175G108 | $9.4M | 4,769,164 | 0.2% |
| Verve Therapeutics Inc | COM | 92539P101 | $9.1M | 650,000 | 0.2% |